Successful discontinuation rate · participants with long‐term antidepressants for depressive disorders
1 finding from 1 review
Risk of relapse (as defined by study authors) (HR) · participants with long‐term antidepressants for depressive disorders
Discontinuation with high‐intensity psychological interventions showed no clear difference in risk of relapse (as defined by study authors) (HR) compared with continuation (low certainty).
1 finding from 1 review
Withdrawal symptoms · participants with long‐term antidepressants for depressive disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with long‐term antidepressants for depressive disorders
1 finding from 1 review
Depressive symptoms · participants with long‐term antidepressants for depressive disorders
1 finding from 1 review
Anxiety · participants with long‐term antidepressants for depressive disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with long‐term antidepressants for depressive disorders
1 finding from 1 review
Social and occupational functioning · participants with long‐term antidepressants for depressive disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Restoration survival · Permanent posterior teeth with single-surface cavities
Single-surface high-viscosity glass-ionomer ART restorations in permanent teeth had high 2-year survival (93%, 95% CI 89-95%); evidence ungraded.
6 findings from 1 review
Show 3 more findings
Restoration survival · Primary posterior teeth with single-surface cavities
Single-surface high-viscosity glass-ionomer ART restorations in primary teeth had high 2-year survival (93%, 95% CI 91-94%); evidence ungraded.
3 findings from 1 review
Overall survival (OS) · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate (ORR), · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (high dose interferon) plus chemotherapy changes overall response rate (ORR), measured after 8 weeks of treatment and… compared with neoadjuvant chemotherapy (very low certainty).
1 finding from 1 review
Time to recurrence ‐ not measured · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Success or failure of restoration (as defined by the USPHS criteria) · Children with carious primary teeth
ART with high-viscosity GIC and amalgam had similar class I restoration success at 24 months (ungraded).
2 findings from 1 review
RR 1.07 [0.91, 1.27]
3 studies
GRADE not reported
RR 0.93 [0.83, 1.06]
3 studies
GRADE not reported
Restoration survival · Primary posterior teeth with multiple-surface cavities
Multiple-surface high-viscosity glass-ionomer ART restorations in primary teeth had moderate 2-year survival (62%, 95% CI 51-73%); evidence ungraded.
3 findings from 1 review
Restoration survival · Permanent posterior teeth with multiple-surface cavities
Multiple-surface high-viscosity glass-ionomer ART restorations in permanent teeth had high 1-year survival (86%, 95% CI 59-98%); evidence ungraded.
3 findings from 1 review
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review